Agomelatina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Agomelatina" in Italian language version.

refsWebsite

Global rank Italian rank

9doi.org

2^nd place

7^th place

7nih.gov

4^th place

9^th place

2google.it

215^th place

4^th place

2europa.eu

68^th place

57^th place

1cochranelibrary.com

low place

1cambridge.org

305^th place

508^th place

1sagepub.com

731^st place

1,032^nd place

1springer.com

274^th place

393^rd place

1aspetjournals.org

6,663^rd place

5,217^th place

1tandfonline.com

507^th place

821^st place

aspetjournals.org

jpet.aspetjournals.org

(EN) M. J. Millan, A. Gobert e F. Lejeune, The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways, in Journal of Pharmacology and Experimental Therapeutics, vol. 306, n. 3, 1º settembre 2003, pp. 954–964, DOI:10.1124/jpet.103.051797. URL consultato il 27 giugno 2023.

cambridge.org

(EN) Corrado Barbui, Thomas Becker e Andrea Cipriani, Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials, in The British Journal of Psychiatry, vol. 203, n. 3, 2013/09, pp. 179–187, DOI:10.1192/bjp.bp.112.120196. URL consultato il 26 aprile 2019.

cochranelibrary.com

Giuseppe Guaiana, Sumeet Gupta e Debbie Chiodo, Agomelatine versus other antidepressive agents for major depression ^{[collegamento interrotto]}, in Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd, 10 novembre 2010, DOI:10.1002/14651858.cd008851. URL consultato il 26 aprile 2019.

doi.org

dx.doi.org

Giuseppe Guaiana, Sumeet Gupta e Debbie Chiodo, Agomelatine versus other antidepressive agents for major depression ^{[collegamento interrotto]}, in Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd, 10 novembre 2010, DOI:10.1002/14651858.cd008851. URL consultato il 26 aprile 2019.
(EN) Corrado Barbui, Thomas Becker e Andrea Cipriani, Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials, in The British Journal of Psychiatry, vol. 203, n. 3, 2013/09, pp. 179–187, DOI:10.1192/bjp.bp.112.120196. URL consultato il 26 aprile 2019.
(EN) Robert H. Howland, A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression, in Drug Safety, vol. 34, n. 9, 1º settembre 2011, pp. 709–731, DOI:10.2165/11593960-000000000-00000. URL consultato il 26 aprile 2019.
(EN) Anthony Cleare, Cm Pariante e Ah Young, Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines, in Journal of Psychopharmacology, vol. 29, n. 5, 2015-05, pp. 459–525, DOI:10.1177/0269881115581093. URL consultato il 28 giugno 2023.
(EN) Sidney H. Kennedy e Sakina J. Rizvi, Agomelatine in the treatment of major depressive disorder, in CNS Drugs, vol. 24, n. 6, 1º giugno 2010, pp. 479–499, DOI:10.2165/11534420-000000000-00000. URL consultato il 28 giugno 2023.
(EN) M. J. Millan, A. Gobert e F. Lejeune, The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways, in Journal of Pharmacology and Experimental Therapeutics, vol. 306, n. 3, 1º settembre 2003, pp. 954–964, DOI:10.1124/jpet.103.051797. URL consultato il 27 giugno 2023.
(EN) Dorra Dridi, Amina Zouiten e Hedi Ben Mansour, Depression: chronophysiology and chronotherapy, in Biological Rhythm Research, vol. 45, n. 1, 2 gennaio 2014, pp. 77–91, DOI:10.1080/09291016.2013.797657. URL consultato il 27 giugno 2023.

doi.org

(EN) Robert H. Howland, A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression, in Drug Safety, vol. 34, n. 9, 1º settembre 2011, pp. 709–731, DOI:10.2165/11593960-000000000-00000. URL consultato il 26 aprile 2019.
(EN) Sidney H. Kennedy e Sakina J. Rizvi, Agomelatine in the treatment of major depressive disorder, in CNS Drugs, vol. 24, n. 6, 1º giugno 2010, pp. 479–499, DOI:10.2165/11534420-000000000-00000. URL consultato il 28 giugno 2023.

europa.eu

ema.europa.eu

"Relazione al pubblico di valutazione europea Valdoxan (EPAR)

emea.europa.eu

Refusal CHMP Assessment Report for Valdoxan (Agomelatine)^{[collegamento interrotto]};

google.it

books.google.it

(EN) David Taylor, Carol Paton e Shitij Kapur, The Maudsley Prescribing Guidelines in Psychiatry, Wiley, 2 aprile 2012, ISBN 978-0-470-97948-8. URL consultato il 28 giugno 2023.
(EN) British Medical Association e Royal Pharmaceutical Society of Great Britain, BNF 65: British National Formulary : March 2013-September 2013, British Medical Association and Royal Pharmaceutical Society of Great Britain, 2013, ISBN 978-0-85711-084-8. URL consultato il 28 giugno 2023.

nih.gov

ncbi.nlm.nih.gov

Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007 Nov;68(11):1723-32. PMID 18052566
Goodwin GM, Emsley R, Rembry S, Rouillon F; Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009 Aug;70(8):1128-37. PMID 19689920
Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010 Apr;30(2):135-44. PMID 20520286
Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry. 2010 May;71(5):616-26. PMID 20361916
Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol. 2010 Nov;25(6):305-14. PMID 20856123
Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008 Oct;28(5):561-6. PMID 18794654
Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003 Sep;306(3):954-64. PubMed PMID 12750432

sagepub.com

journals.sagepub.com

(EN) Anthony Cleare, Cm Pariante e Ah Young, Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines, in Journal of Psychopharmacology, vol. 29, n. 5, 2015-05, pp. 459–525, DOI:10.1177/0269881115581093. URL consultato il 28 giugno 2023.

springer.com

adisinsight.springer.com

Agomelatine - Servier - AdisInsight, su adisinsight.springer.com. URL consultato il 26 aprile 2019.

tandfonline.com

(EN) Dorra Dridi, Amina Zouiten e Hedi Ben Mansour, Depression: chronophysiology and chronotherapy, in Biological Rhythm Research, vol. 45, n. 1, 2 gennaio 2014, pp. 77–91, DOI:10.1080/09291016.2013.797657. URL consultato il 27 giugno 2023.